What it is
Ipamorelin is a synthetic pentapeptide first described in the late 1990s. It is structurally classified as a growth hormone secretagogue and is one of the more selective ghrelin receptor agonists in the research peptide category.
How it works
In research models, Ipamorelin is studied as a selective agonist at the ghrelin/GHS-R1a receptor in the anterior pituitary. Its selectivity profile in research settings is associated with minimal observed cross activity at cortisol and prolactin pathways relative to older GHRPs.
What researchers explore it for
Researchers have explored Ipamorelin in growth hormone axis research, in combination pairing research with GHRH analogs such as CJC-1295 (no DAC), and in receptor selectivity research.
Safety and interactions
Research interactions of note include co administration with GHRH analogs and with other ghrelin receptor agonists, which is commonly studied as a synergistic pairing. Ipamorelin is for laboratory research use only and is not for human consumption. Not medical advice. Not intended to diagnose, treat, cure, or prevent any disease.
Research notes
Peptide family: ghrelin receptor agonists (GHRPs). Frequently compared with GHRP-2, GHRP-6, and Hexarelin. Commonly researched alongside CJC-1295 (no DAC). Lyophilized powder; reconstitution and storage handling per laboratory protocols.
Related peptides: CJC-1295 (no DAC) · GHRP-2 · GHRP-6 · Hexarelin